Page last updated: 2024-08-24

valsartan and cyclic gmp

valsartan has been researched along with cyclic gmp in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.56)18.2507
2000's6 (33.33)29.6817
2010's9 (50.00)24.3611
2020's2 (11.11)2.80

Authors

AuthorsStudies
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R1
Carey, RM; de Gasparo, M; El-Kersh, M; Siragy, HM1
Carey, RM; De Gasparo, M; El-Kersh, MA; Siragy, HM; Webb, RL1
Abadir, PM; Carey, RM; Siragy, HM1
Isaka, N; Ito, M; Kaibuchi, K; Kongo, M; Kureishi, Y; Moriki, N; Nakakuki, T; Nakano, T; Okamoto, R; Seko, T1
Barker, TA; Berk, BC; Kennedy, AJ; Korshunov, VA; Massett, MP; Mohan, AM1
Brown, NJ; Gebretsadik, T; LeFebvre, J; Murphey, LJ; Petro, JR; Shintani, A1
Akimoto, T; Fujita, D; Hirata, Y; Kiyosue, A; Komuro, I; Morishita, Y; Myojo, M; Nagai, R; Nagata, D; Satonaka, H; Takahashi, M1
Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Nakagawa, T; Ogawa, H; Sueta, D1
Ayalasomayajula, S; Greeley, M; Hsiao, HL; Kode, K; Langenickel, TH; Pal, P; Petruck, J; Prescott, MF; Rajman, I; Schuehly, U; Sunkara, G; Zhou, W1
Chrysant, SG1
Bianchi, F; Cotugno, M; Forte, M; Madonna, M; Marchitti, S; Rubattu, S; Stanzione, R; Volpe, M1
Ayalasomayajula, S; Buchbjerg, J; Golor, G; Hinder, M; Langenickel, TH; Pal, P; Prescott, MF; Schuehly, U; Sunkara, G1
Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH1
Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Prescott, MF; Rocha, R; Velazquez, EJ1
Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L1
Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB1

Reviews

2 review(s) available for valsartan and cyclic gmp

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Journal of the American Society of Hypertension : JASH, 2017, Volume: 11, Issue:7

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Clinical Trials as Topic; Cough; Cyclic GMP; Diuresis; Drug Combinations; Heart Failure; Heart Ventricles; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan; Vasodilation

2017

Trials

4 trial(s) available for valsartan and cyclic gmp

ArticleYear
Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 320, Issue:3

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Bradykinin; Bradykinin B2 Receptor Antagonists; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Female; Heart Rate; Humans; Hypertension; Male; Receptor, Bradykinin B2; Renin; Sodium; Tetrazoles; Valine; Valsartan

2007
Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
    Clinical pharmacology and therapeutics, 2018, Volume: 103, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Double-Blind Method; Drug Combinations; Drug Interactions; Humans; Hypertension; Male; Middle Aged; Sildenafil Citrate; Tetrazoles; Valsartan

2018
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:9

    Topics: Administration, Oral; Adult; Aminobutyrates; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Cyclic GMP; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Drug Monitoring; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Middle Aged; Nitroglycerin; Tetrazoles; Valsartan

2018
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
    European heart journal, 2019, 10-21, Volume: 40, Issue:40

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cyclic GMP; Drug Combinations; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Tetrazoles; Treatment Outcome; Troponin; Valsartan

2019

Other Studies

12 other study(ies) available for valsartan and cyclic gmp

ArticleYear
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
    Cardiovascular research, 1999, Volume: 42, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan

1999
Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
    Hypertension (Dallas, Tex. : 1979), 2001, Volume: 38, Issue:2

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Cyclic GMP; Drug Synergism; Extracellular Space; Imidazoles; Kidney; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Tetrazoles; Valine; Valsartan

2001
Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
    Journal of hypertension, 2002, Volume: 20, Issue:6

    Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Female; Imidazoles; Injections, Intravenous; Kidney; Losartan; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan

2002
Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:4

    Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Imidazoles; Kidney; Mice; Mice, Knockout; Nitrates; Nitric Oxide; Nitrites; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Receptors, Angiotensin; Receptors, Bradykinin; Sodium; Tetrazoles; Valine; Valsartan

2003
RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:4

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Cells, Cultured; Cyclic AMP; Cyclic GMP; Hypertension; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Stroke; Tetrazoles; Valine; Valsartan

2004
Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:5

    Topics: Amlodipine; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Carotid Artery, Common; Cyclic GMP; Male; Rats; Rats, Inbred BN; Receptor, Angiotensin, Type 2; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan

2006
Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Benzoates; Cyclic GMP; Enzyme Activation; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction; Telmisartan; Tetrazoles; Valine; Valsartan

2014
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
    American journal of hypertension, 2015, Volume: 28, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Circadian Rhythm; Cyclic GMP; Drug Combinations; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrosis; Heart; Hypertension; Inflammation; Male; Myocardium; Neprilysin; Oxidative Stress; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Tetrazoles; Valsartan; Vascular Remodeling

2015
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
    Journal of hypertension, 2018, Volume: 36, Issue:9

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Drug Combinations; Hypertension; Male; Neprilysin; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valsartan

2018
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2019, Feb-01, Volume: 128

    Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan

2019
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Cardiovascular research, 2021, 04-23, Volume: 117, Issue:5

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling

2021
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    International journal of molecular sciences, 2021, Mar-30, Volume: 22, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left

2021